Want to see ORKA full AI Analyst Report?
Top Page
Oruka Therapeutics
(NASDAQ:ORKA)
Select Model
Select Model
Rating:60Neutral
Price Target:
$84.00
▼(-15.53% Downside)
Action:Reiterated
Date:08/25/26
ORKA scores as moderate overall, driven primarily by a strong, low-debt balance sheet but offset by a pre-revenue profile with widening losses and increasing cash burn. Technicals are a supportive secondary factor with strong price trend and positive momentum. Valuation remains a headwind due to negative earnings (negative P/E) and no dividend support, while corporate events are mildly positive but not decisive.
Positive Factors
Low leverage and strong capital base
Extremely low leverage gives Oruka substantial financial flexibility while it advances its clinical programs. The sharply larger asset base indicates a well-capitalized platform, reducing balance-sheet pressure and supporting continued development investment over the next several quarters.
Negative Factors
Pre-revenue business model
Oruka has no product revenue to offset research and development spending, leaving its financial profile dependent on clinical progress and eventual commercialization. Until revenue or partnering inflows emerge, the company lacks an internally generated funding engine for its operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and strong capital base
Extremely low leverage gives Oruka substantial financial flexibility while it advances its clinical programs. The sharply larger asset base indicates a well-capitalized platform, reducing balance-sheet pressure and supporting continued development investment over the next several quarters.
Read all positive factors
Oruka Therapeutics (ORKA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.24B
Dividend Yield64.52%
Average Volume (3M)981.12K
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue GrowthN/A
EPS Growth32.27%
CountryUS
Employees68
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.47
Shares Outstanding66,209,700
10 Day Avg. Volume918,861
30 Day Avg. Volume981,115
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.93
Price to Sales (P/S)0.00
P/FCF Ratio-15.64
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-44.87K
Enterprise Value/Ebitda-36.11
Forecast
1Y Price Target
$154.50Price Target Upside55.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.4
Revenue Forecast (FY)N/A
Oruka Therapeutics Business Overview & Revenue Model
Company Description
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 tha...
How the Company Makes Money
As a clinical-stage biotechnology company, Oruka Therapeutics does not have publicly available information indicating it generates recurring revenue from product sales. null...
Oruka Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
82
Very Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -114.00K | -83.00K | -27.00K | -114.00K | -91.00K | -93.00K |
| EBITDA | -141.65M | -105.35M | -82.23M | -9.81M | -19.23M | -9.64M |
| Net Income | -132.89M | -105.43M | -83.72M | -9.93M | -19.32M | -9.74M |
Balance Sheet | ||||||
| Total Assets | 1.14B | 488.62M | 396.02M | 43.09M | 54.92M | 50.43M |
| Cash, Cash Equivalents and Short-Term Investments | 873.56M | 337.04M | 375.65M | 42.45M | 53.36M | 49.07M |
| Total Debt | 2.55M | 1.93M | 968.00K | 383.00K | 483.00K | 450.00K |
| Total Liabilities | 24.84M | 16.69M | 13.80M | 1.41M | 3.88M | 3.91M |
| Stockholders Equity | 1.11B | 471.93M | 382.22M | 41.67M | 51.04M | 46.52M |
Cash Flow | ||||||
| Free Cash Flow | -101.15M | -88.42M | -58.03M | -10.91M | -18.80M | -7.74M |
| Operating Cash Flow | -100.92M | -88.21M | -57.84M | -10.91M | -18.76M | -7.72M |
| Investing Cash Flow | -569.86M | -96.75M | -330.13M | -2.00K | -43.00K | -19.00K |
| Financing Cash Flow | 873.85M | 170.31M | 449.54M | 0.00 | 23.09M | 48.45M |
Oruka Therapeutics Technical Analysis
Neutral
99.44
Price Trends
91.07
Negative
87.35
Negative
67.06
Positive
Market Momentum
-3.86
Negative
45.20
Neutral
58.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORKA, the sentiment is Neutral. The current price of 99.44 is above the 20-day moving average (MA) of 80.27, above the 50-day MA of 91.07, and above the 200-day MA of 67.06, indicating a neutral trend. The MACD of -3.86 indicates Negative momentum. The RSI at 45.20 is Neutral, neither overbought nor oversold. The STOCH value of 58.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ORKA.
Oruka Therapeutics Risk Analysis
Oruka Therapeutics disclosed 1 risk factors in its most recent earnings report. Oruka Therapeutics reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oruka Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $4.01B | 144.34 | 15.05% | ― | 76.11% | ― | |
60 Neutral | $5.24B | -32.36 | -20.76% | 64.52% | ― | 32.27% | |
55 Neutral | $5.86B | -10.06 | -69.59% | ― | ― | 1.28% | |
53 Neutral | $2.17B | -5.32 | -84.13% | ― | ― | -63.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $878.30M | -2.77 | -82.68% | ― | ― | -37.48% | |
43 Neutral | $909.10M | -1.79 | -102.97% | ― | -63.11% | 15.36% |
* Healthcare Sector Average
ORKA
Oruka Therapeutics
81.15
54.02
199.12%
IMVT
Immunovant
29.10
10.36
55.28%
ARQT
Arcutis Biotherapeutics
32.20
12.12
60.36%
MLTX
MoonLake Immunotherapeutics
12.34
2.88
30.44%
VERA
Vera Therapeutics
29.05
0.85
3.01%
ALMS
Alumis Inc.
6.82
2.21
47.94%
Oruka Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Oruka Therapeutics Appoints Todd Edwards Chief Commercial Officer
Positive
Aug 24, 2026
On July 22, 2026, Oruka Therapeutics appointed veteran commercial executive Todd Edwards as Chief Commercial Officer, with his employment commencing on August 24, 2026. Edwards brings extensive commercialization experience from senior roles at Arc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.